Jsc Grindeks

Latvian Institute of Organic Synthesis

Biolipox Ab

Ditesan Ltd.

Other

Tetra, Sia

Acure Pharma Ab

Uniwersytet Jagiellonski

Grindeks, a Joint Stock Company

Kalvins, Prof. Dr., Ivars

Ivars Kalvins

Maija Dambrova

Einars Loza

Edgars Liepins

Janis Kuka

Osvalds Pugovics

Solveiga Grinberga

Ilmars Stonans

Irina Shestakova

Reinis Vilskersts

Ilona Domracheva

Benjamin Pelcman

Edgars Suna

Vita Ozola

Liga Zvejniece

Maksims Vorona

Antons Lebedevs

Martins Katkevics

Kristofer Olofsson

Anna Skottner

Torbjörn Lundstedt

Victor Andrianov

Arne Boman

Aleksandrs Chernobrovijs

Grigory Veinberg

Dite Venskus

Aleksandrs Cernobrovijs

Dace Pjanova

Ramona Petrovska

Jurgis Auzins

Daina Lola

Grigorijs Veinbergs

Pavels Arsenjans

Per Andersson

Anatolijs Birmans

Dace Katkevica

Gunars Duburs

Jelena Vasiljeva

Elina Jaschenko

Iveta Kanepe

Viktor Adrianov

Wesley Schaal

Peteris Trapencieris

Baiba Svalbe

Edijs Vavers

Anatolijs Misnovs

Laura Krasnova

Ilze Adlere

Zigmars Andzans

Signe Grinberga

Aivars Krauze

Marina Makrecka

Daina Gustina

Ilga Misane

Maris Veveris

Agnija Ievina

Viktors Andrianovs

Pugovics Osvalds

Victor Adrianov

Kamil Kus

Valerjans Kauss

Anita Gulbe

Iveta Kanepe-Lapsa

Stefan Chlopicki

The present invention relates to a novel cancer metastasis preventing and curing selenopheno[h]chromene derivatives, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment and/or prevention of primary cancer and its metastasis by administration of such substances. 

Antimetastatic 2H-selenopheno[3,2-h]chromenes, synthesis thereof, and methods of using same agents

In a method for manufacturing a modified enterovirus of ECHO 7 type by modification of native ECHO 7 virus, isolated by a known method from human feces and identified by genome sequence, the modification is performed initially conducting the virus adaptation in cancer cells, attenuated by anti-cancer agent dacarbazine, further passaging the modified virus in human embryonal fibroblast culture, followed by propagation in human melanoma cells and further passaging in human embryonal fibroblast culture, that was treated by ribavirin, isolation and purification by known method. The modified virus is suitable for treating various tumors.

Genetically stable oncolytic RNA virus, method of manufacturing and use thereof

Salts of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium, method of preparation thereof and use in the treatment of cardiovascular disease.

Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease

In a method for manufacturing a modified enterovirus of ECHO 7 type by modification of native ECHO 7 virus, isolated by a known method from human feces and identified by genome sequence, the modification is performed initially conducting the virus adaptation in cancer cells, attenuated by anti-cancer agent dacarbazine, further passaging the modified virus in human embryonal fibroblast culture, followed by propagation in human melanoma cells and further passaging in human embryonal fibroblast culture, that was treated by ribavirin, isolation and purification by known method. The modified virus is suitable for treating various tumours.

Use of 2-(5S-Methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetamide or its pharmaceutically acceptable salt in manufacture of a medicament for prophylaxis and treatment of seizure.

Use of 2-(5S-methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures

The thieno[2,3-b]pyridines of general formula (I), whereinRis Me, CH, 3,4,5-(OMe)CH, NH;Ris H, CN, COMe, COOCalkyl, COOCHOMe, COOCHOPr(n);Ris CHR, 3,4-OCHO&#x2014;CH; 2-furanyl;

Thieno [2,3-b] pyridines as multidrug resistance modulators

New compound 4-[ethyl(dimethyl)ammonio]butanoate, method of preparation thereof and use in the treatment of cardiovascular disease.

Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease

4-[(Haloalkyl)(dimethyl)ammonio]butanoates of formula 

4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease

Novel betaine salts of acetylsalicylic acid, namely 4-trimethylammoniobutanoate acetylsalicylic acid addition salt (gamma-butyrobetaine acetylsalicylate), L-carnitine acetylsalicylic acid addition salt and 3-(trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt. Use of meldonium acetylsalicylate as antiplatelet agent for treating various pathologies induced by platelet aggregation, anti-inflammatory and antihyperlipidemic agent.

Acetylsalicylic acid salts

The invention relates to the 5S,4R-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with cognition enhancing activity of high pharmacological value and to its preparation method which includes the synthesis of 5S-methyl-4R-phenylpyrrolidin-2-one, its N-alkylation with ethyl haloacetate and the treatment of intermediate ethyl 2-(5S-methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetate with ammonia.

[object Object]

 There is provided compounds of formula (I), wherein X, Q, T, Y, R, R, R, Rand Rhave meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation.

Indoles useful in the treatment of inflammation

There is provided a compound of formula: (I), wherein X, R, R, R, R, Rand Rhave meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of microsomal prostaglandin E synthase-1 is desired and/or required, and particularly in the treatment of inflammation. 

The present invention provides novel compounds and use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: Wherein X and Y are independently chosen from O, N, S and (CH), where n is 0, 1, 2, 3, 4, or 5, or a combination of these and may contain carbon-carbon multiple bonds and branched chains as well as alicyclic and heterocyclic groups; Q is H or OH; Rand Rcan be either the same or different and are chosen from hydrogen or the residue of an aromatic group as listed in Scheme 1 and the pharmacologically active salts thereof 

Compounds acting as melanocortin receptor ligands

Described are new 1-aziridino-1-hydroxyiminomethyl derivatives with the general formula (I), wherein R is able to is a single bond or a linker moiety capable of covalently bonding two aziridine oxime groups, Rand Rindependently of one another are selected from the group consisting of &#x2014;H, &#x2014;CH, &#x2014;CH, &#x2014;CN, &#x2014;COOH, &#x2014;COOCH, &#x2014;COOCH, &#x2014;CONH, or &#x2014;CHgroup, and n is the whole number 2, provided that Rand Rare not both &#x2014;H and provided that Ris not &#x2014;H if Ris &#x2014;CHand Ris not &#x2014;CHif Ris &#x2014;H The compounds of general formula (I) show antitumor activity.

1-aziridino-1-hydroxyiminomethyl-derivates, method for the production thereof and medicaments containing said compounds

Growing community of inventors

Ikskile, Latvia

Ivars Kalvins